Follow Us
Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Drug discovery involving artificial intelligence (AI) tools has quickly occupied significant territory in the pharmaceutical industry. One study found that the number of startup drug candidate pipelines employing AI is roughly equivalent to 50% of the preclinical programs of big pharmaceutical firms. See, Jayatunga et al., “AI in Small-Molecule Drug Discovery: a Coming Wave?” Nature Reviews, March 2022. The prevalence of AI has generally led to significantly reduced drug discovery timelines. Current research data indicates that AI-driven discovery pipelines on average reach the preclinical phase within four years, compared to the conventional expectation of five to six years. Id.
Continue reading by getting
started with a subscription.
By Reid Knabe and Bita Rahebi
This article describes certain key developments in the period from passage of the CHIPS Act through the present day, and provides a brief survey of key grantmaking and investment activity by U.S. government agencies since passage of the Act.
LLM Customization With A Path to Human Inventorship and Patent Rights
By Jim Soong
A statutory predicate to the contractual outcome regarding ownership of patent rights is the requirement of a sufficient contribution by a natural person in the effort that yielded the output. The issues implicated by this requirement are one development among more to come as patent law and policy try to catch up to proliferating AI technology.
Adidas Stripe Design Battle Reveals Intricacies of Trademarks In the Fashion World
By Nicole D. Galli, Laura Talley Geyer and Alexa Elder
Although the bitter legal battle between Adidas and Thom Browne is far from over on either side of the pond, the case illustrates the challenges of ensuring trademark protection for simple and widely employed design elements.
Is It Possible to Reconcile the Two Sides In the AI Copyright Debate?
By Maria Dinzeo
The points and counterpoints brought up by experts at a Stanford Law conference provide insight on the future relationship between AI and copyright creators.
Copyright © ALM Global, LLC. All Rights Reserved.
